Studying Genes in Samples From Younger Patients With Rhabdomyosarcoma
NCT ID: NCT01585376
Last Updated: 2016-05-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
58 participants
OBSERVATIONAL
2012-04-30
2016-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research trial studies genes in samples from younger patients with rhabdomyosarcoma.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas
NCT01567046
Studying Biomarkers in Samples From Patients With Rhabdomyosarcoma
NCT01433237
Studying Genes in Samples From Younger Patients With Adrenocortical Tumor
NCT01528956
Protein Expression in Samples From Young Patients With Rhabdomyosarcoma
NCT01426945
Biomarker in Tumor Tissue Samples From Patients With Rhabdomyosarcoma
NCT01365962
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To obtain a larger cohort of rhabdomyosarcoma samples (alveolar and embryonal) to establish a more accurate estimate of the frequency of particular genetic lesions.
* To provide the statistical power to establish an unambiguous connection between focal genetic lesions, histological subtype, and outcome for patients with rhabdomyosarcoma.
OUTLINE: DNA samples are analyzed in solid and liquid phase for exons of all genes mutated from previous discovery. DNA is then eluted and sequenced by illumina platform.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
mutation analysis
nucleic acid sequencing
laboratory biomarker analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Matched genomic deoxyribonucleic acid (DNA) from tumor and germline samples from patients diagnosed with rhabdomyosarcoma (alveolar or embryonal)
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* Not specified
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Children's Oncology Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alberto S. Pappo, MD
Role: PRINCIPAL_INVESTIGATOR
St. Jude Children's Research Hospital
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COG-ARST12B3
Identifier Type: OTHER
Identifier Source: secondary_id
ARST12B3
Identifier Type: OTHER
Identifier Source: secondary_id
CDR0000732173
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2012-00729
Identifier Type: REGISTRY
Identifier Source: secondary_id
ARST12B3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.